A curative treatment for Alzheimer's disease is approved within 20 years.

Question

Six frontier AI models put this at 12% by 21 Sept 2076. Full reasoning from every model.

WillHappen.ai · Accepted Answer

12% — the median of 5 frontier models, resolving by 2076-09-21.

Answer

Gemini (Google): 12% — A true cure requires neural regeneration rather than mere plaque clearance, a threshold no clinical candidate has yet approached. FDA-approved therapies like lecanemab only modestly slow cognitive decline; none regenerate dead neurons or halt downstream cascades. A drug entering Phase 1 today needs 10 to 15 years to gain approval, meaning any 2046 curative agent must essentially exist in labs now. Discovery of scalable neurogenesis or cellular reprogramming in primate brains by 2035 would be the primary sign to raise these odds.

Answer

Claude (Anthropic): 12% — Whether disease-modifying drugs evolve into a true cure rather than modest slowing within two decades. Current approved drugs (lecanemab, donanemab) only modestly slow decline, not cure, after decades of amyloid-focused research. Alzheimer's is multifactorial with unclear root cause, and no regulator has ever approved a 'cure' claim for it. Tau-targeting, gene therapy, or early biomarker-driven prevention could change trajectory, but translating to a reliable cure by 2046 is a high bar.

Answer

GPT (OpenAI): 18% — This hinges on whether Alzheimer’s biology yields a reversible target, not merely earlier diagnosis or slower decline. FDA approvals through 2026, including lecanemab and donanemab, modestly slow decline but have not restored lost cognition. A literal cure must reliably halt and reverse disease across established cases; no late-stage program has shown that threshold. Twenty years permits major platform advances, but neurodegeneration has resisted curative therapies despite decades of trials; durable reversal data would sharply raise…

Answer

DeepSeek (DeepSeek): 12% — A true cure needs a therapy that reverses existing plaques and tangles and restores lost neurons, not just slows decline. Anti-amyloid antibodies like lecanemab and donanemab were approved in 2023-2024 but only slow decline by ~0.5 points on CDR-SB, far from reversal. The FDA approves drugs on biomarker or surrogate endpoints, so a 'cure' label would require a sponsor to run a multi-year trial showing cognitive restoration, which no… Base rate for cures in neurodegenerative disease is near zero; the 20-year window is long enough for a tau or neuroinflammation breakthrough, but the biology of neuronal…

Answer

Qwen (Alibaba): 12% — No therapy has ever reversed neurodegeneration once symptoms appear; 20 years is short for a disease with decades-long prodrome. Lecanemab and donanemab slow decline ~27-35% but don't halt or reverse disease; no Phase III agent targets a curative mechanism. FDA approval requires pivotal trials showing functional restoration, not just biomarker clearance—no such trial design exists today. Base rate: zero neurodegenerative diseases have been cured in 50 years of drug development; even HIV remains managed, not cured.

A curative treatment for Alzheimer's disease is approved within 20 years.

A clinically proven cure for dementia is approved before 2032.

A disease-reversing cure for Alzheimer's disease receives FDA approval before 2035.

A definitive cure for at least five major cancers is approved within 10 years.

A definitive cure for cancer is developed and approved within 20 years.